Monocyclic compounds useful as GPR120 modulators
Provided herein are compounds, compositions including them, and methods of modulating GPR120 activity and treating diseases mediated by GPR120 by administering such compounds and compositions.
1. A compound of formula I:
or a tautomer thereof, or an isotopomer thereof, or a stereoisomer thereof, or a pharmaceutically acceptable salt of each thereof, or a prodrug thereof, or a pharmaceutically acceptable solvate of each of the foregoing, wherein
each A independently is N or CH;
B is N or CR 2 wherein R 2 is H, halogen, CN, OCH 3 , OCF 3 , —NH-acyl, an alkyl group, a substituted alkyl group, a carboxamido or a sulfonamido group, a substituted carboxamido or a sulfonamido group, a cycloalkyl or heterocyclyl group, a substituted cycloalkyl or heterocyclyl group, an aryl or heteroaryl group, or a substituted aryl or heteroaryl group;
with the provision that at least one of A or B is N;
W is a covalent bond or O;
each X independently is CH, CR 3 or N wherein R 3 is halogen, alkyl, alkoxy, or CN;
Y is SO 2 , CO, CH 2 , —C(CH 3 ) 2 —, or —CH(CH 3 )—;
Z is —CH 2 —, —CH(CH 3 )—, —C(CH 3 ) 2 —, —C(CH 2 CH 2 )—, CO, —(CO)CH 2 —, —CH 2 CH 2 —, or —CHCH—,
R 1 is an alkyl group, a substituted alkyl group, a 3-7 membered cycloalkyl or heterocyclyl group, a substituted 3-7 membered cycloalkyl or heterocyclyl group, an aryl or heteroaryl group, or a substituted aryl or heteroaryl group.
2. The compound of claim 1 of formula selected from:
wherein
W is a covalent bond or O;
each X independently is CH, CR 3 or N wherein R 3 is halogen, alkyl, alkoxy, or CN;
Y is SO 2 , CO, CH 2 , —C(CH 3 ) 2 —, or —CH(CH 3 )—;
Z is —CH 2 —, —CH(CH 3 )—, —C(CH 3 ) 2 —, —C(CH 2 CH 2 )—, CO, —(CO)CH 2 —, —CH 2 CH 2 —, or —CHCH—;
R 1 is an alkyl group, a substituted alkyl group, a 3-7 membered cycloalkyl or heterocyclyl group, a substituted 3-7 membered cycloalkyl or heterocyclyl group, an aryl or heteroaryl group, or a substituted aryl or heteroaryl group; and
R 2 is H, halogen, CN, OCH 3 , OCF 3 , NH-acyl, an alkyl group, a substituted alkyl group, a carboxamide or a sulfonamido group, a substituted carboxamide or a sulfonamido group, a cycloalkyl or heterocyclyl group, a substituted cycloalkyl or heterocyclyl group, or an aryl or heteroaryl group, or a substituted aryl or heteroaryl group.
3. A compound of the structure
or a tautomer thereof, or an isotopomer thereof, or a stereoisomer thereof, or a pharmaceutically acceptable salt of each thereof, or a prodrug thereof, or a pharmaceutically acceptable solvate of each of the foregoing.
4. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.
5. A method for agonizing GPR120, comprising contacting the GPR120 with a compound of claim 1 .
6. A method for modulating metabolism in a mammal in need thereof, comprising contacting GPR120 in the mammal with an amount of the compound of claim 1 effective to modulate metabolism in the mammal.
7. A method for modulating metabolism in a mammal in need thereof, comprising administering to the mammal an amount of the composition of claim 4 effective to modulate metabolism in the mammal.
8. A method for reducing inflammation in a mammal, comprising contacting GPR120 in the mammal with an amount of the compound of claim 1 effective to reduce the inflammation.
9. A method for reducing inflammation in a mammal, comprising administering to the mammal an amount of the composition of claim 4 effective to reduce the inflammation.
10. A method for reducing neuroinflammation in a mammal, comprising contacting GPR120 in the mammal with an amount of the compound of claim 1 effective to reduce the neuroinflammation.
11. A method for reducing neuroinflammation in a mammal, comprising administering to the mammal an amount of the composition of claim 4 effective to reduce neuroinflammation.
12. A method for treating diabetes, pre-diabetes or metabolic syndrome, or one or more symptoms of each thereof in a mammal, comprising contacting GPR120 in the mammal with a therapeutically effective amount of the compound of claim 1 .
13. A method for treating diabetes, pre-diabetes or metabolic syndrome, or one or more symptoms of each thereof in a mammal, comprising administering to the mammal a therapeutically effective amount of the composition of claim 4 .
14. A method for treating steatohepatitis in a mammal, comprising contacting GPR120 in the mammal with a therapeutically effective amount of the compound of claim 1 .
15. A method for treating steatohepatitis in a mammal, comprising administering to the mammal a therapeutically effective amount of the composition of claim 4 .
16. A method for treating non-alcoholic steatohepatitis in a mammal, comprising contacting GPR120 in the mammal with a therapeutically effective amount of the compound of claim 1 .
17. A method for treating non-alcoholic steatohepatitis in a mammal, comprising administering to the mammal a therapeutically effective amount of the composition of claim 4 .
18. A method for treating a disorder associated with, leading to, or resulting from neuroinflammation in a mammal, comprising contacting GPR120 in the mammal with a therapeutically effective amount of the compound of claim 1 .
19. A method for treating a disorder associated with, leading to, or resulting from neuroinflammation in a mammal, comprising administering to the mammal a therapeutically effective amount of the composition of claim 4 .
20. A method for treating Alzheimer's disease, Parkinson's disease, frontotemporal dementia, amyotrophic lateral sclerosis or multi-system atrophy, or one or more symptoms of each thereof, in a patient, comprising contacting GPR120 in the patient with a therapeutically effective amount of the compound of claim 1 .